02.08.2007 12:00:00
|
FEI and Scripps Research Institute Provide Open Source Code
FEI (Nasdaq: FEIC) and The Scripps Institute have announced that the
Leginon™ software system, an advanced solution
for automated control and image acquisition from a transmission electron
microscope (TEM), will now be available to the global scientific
community as open source code. The Leginon software was developed by
Scripps with funding from the National Center for Research Resources,
National Institutes of Health and has been marketed by FEI since 2003.
It is most commonly used for Single Particle Analysis (SPA)
applications, where three dimensional models of nanoscale particles are
created.
The Leginon software enables TEM users to collect very large numbers of
high quality images of macromolecules under low dose conditions. The
automated system is integrated with a database that keeps track of all
acquired images, the imaging parameters associated with them, as well as
the relationship between images acquired from the same target at a
variety of scales. The application helps improve throughput for single
particle data acquisition, both by increasing the number of images
acquired as well as the number of different specimens that can be imaged
and analyzed.
"The relationship between FEI and our group at
TSRI was critical to the initial development of Leginon as well as the
subsequent rapid implementation of new features suggested by the user
community,” said Bridget Carragher, Director
of the National Resource for Automated Molecular Microscopy, which is
based at TSRI. Clint Potter, a Co- Director of the Resource added, "The
generosity of FEI in releasing Leginon under an Open Source License
ensures that the software can now continue to be developed by the
scientific community for the benefit of everyone.” "We are pleased to have worked with the
Scripps Research Institute for many years on the Leginon program and we
are happy to make the Leginon software available under an open source
license,” commented Matt Harris, vice
president of FEI’s NanoBiology division. "The
widespread availability of this proven and highly functional software
will accelerate scientific discovery and development in life sciences
for many years to come.”
Leginon software is now available for download subject to the Apache
Open Source License at: www.leginon.org.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest
independent, non-profit biomedical research organizations, at the
forefront of basic biomedical science that seeks to comprehend the most
fundamental processes of life. Scripps Research is internationally
recognized for its discoveries in immunology, molecular and cellular
biology, chemistry, neurosciences, autoimmune, cardiovascular, and
infectious diseases, and synthetic vaccine development. Established in
its current configuration in 1961, it employs approximately 3,000
scientists, postdoctoral fellows, scientific and other technicians,
doctoral degree graduate students, and administrative and technical
support personnel. Scripps Research is headquartered in La Jolla,
California. It also includes Scripps Florida, whose researchers focus on
basic biomedical science, drug discovery, and technology development.
About FEI
FEI (Nasdaq: FEIC) is a global leader in providing innovative
instruments for nanoscale imaging, analysis and prototyping. FEI focuses
on delivering solutions that provide groundbreaking results and
accelerate research, development and manufacturing cycles for its
customers in Semiconductor and Data Storage, Academic and Industrial
R&D, and Life Sciences markets. With R&D centers in North America and
Europe, and sales and service operations in more than 50 countries
around the world, FEI’s Tools for Nanotech™
are bringing the nanoscale within the grasp of leading researchers and
manufacturers. More information can be found online at: www.fei.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.